Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02296242
Title Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors BioMed Valley Discoveries, Inc
Indications

acute myeloid leukemia

bone marrow cancer

Therapies

Ulixertinib

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST